Gastrointestinal Cancer Clinical Trials and Research

Norton Cancer Institute is at the forefront of gastrointestinal cancer treatment research. As principal investigators on numerous trials, our specialist physicians have unparalleled experience with many innovative treatments once they are approved for broad use. Patients also may be eligible to take part in these experimental gastrointestinal cancer treatments. Norton Cancer Institute researchers also contribute to groundbreaking studies and other publications in peer-reviewed journals.

Learn more about participating in a clinical trial at Norton Healthcare.

Current Gastrointestinal Cancer Clinical Trials and Research

Esophageal Cancer

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center International Study of Durvalumab Given Concurrently with Definitive Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

Eligibility Criteria and Other Details

GI-NCIResearch@nortonhealthcare.org

Sponsor: AstraZeneca

Gastric Cancer

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant/Adjuvant Durvalumab and Standard Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and astroesophageal Cancer (GC/GEJC)

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

GI-NCIResearch@nortonhealthcare.org

Sponsor: AstraZeneca

Gastric Cancer

A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC)

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

Eligibility Criteria and Other Details

GI-NCIResearch@nortonhealthcare.org

Sponsor: Seattle Genetics, Inc

Hepatocellular Carcinoma (HCC)

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)

Study Type: Drug Study

Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology

Recently published research

Sponsor: Merck Sharp & Dohme LLC

Metastatic Colorectal Cancer

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

Sponsor: Merck & Co., Inc

Metastatic Esophageal Carcinoma

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma

Study Type: Drug Study

Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute

Sponsor: Merck Sharp & Dohme CORP

Pancreatic Cancer

A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma

Study Type: Device Study

Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology

Recently published research

Eligibility Criteria and Other Details

mary.healey@louisville.edu

Sponsor: AngioDynamics, Inc.

Recent Gastrointestinal Cancer Research Published by Norton Cancer Institute Physicians

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)

Request an Appointment Online

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3500

View All Stories

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Gastrointestinal Cancer Clinical Trials and Research

Gastrointestinal Cancer Clinical Trials and Research

Current Gastrointestinal Cancer Clinical Trials and Research

Esophageal Cancer

Gastric Cancer

Gastric Cancer

Hepatocellular Carcinoma (HCC)

Metastatic Colorectal Cancer

Metastatic Esophageal Carcinoma

Pancreatic Cancer

Recent Gastrointestinal Cancer Research Published by Norton Cancer Institute Physicians

Gastrointestinal Neoplasms[Mesh] AND (Norton[Affiliation])) AND (Louisville[Affiliation])) NOT (Children's[Affiliation])

Appointments

Clinical Trials

Cómo facilitar la preparación de la colonoscopia

Colonoscopy age dropping from 50 to 45 for most

If you’ve been putting off cancer screenings, here’s your guide to catching up

Why get a colon cancer screening if you don’t have a family history?

Colonoscopy prep options: They’ve gotten easier

Cómo facilitar la preparación de la colonoscopia

Colonoscopy age dropping from 50 to 45 for most

If you’ve been putting off cancer screenings, here’s your guide to catching up

Why get a colon cancer screening if you don’t have a family history?

Colonoscopy prep options: They’ve gotten easier

Schedule an Appointment